---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-23-038715"
form_type: "8-K"
ticker: "IONS"
cik: "0000874015"
company_name: "IONIS PHARMACEUTICALS INC"
filed_at: "2023-08-09T23:59:59+00:00"
generated_at: "2026-06-11T23:55:47.241401+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Ionis Q2 2023 revenue up 40% to $188M; eplontersen PDUFA set for Dec 22, 2023

## Summary
- Total revenue $188M in Q2 (+40% YoY); operating loss $91M GAAP, $64M non-GAAP.
- Cash & short-term investments $2.4B; issued $575M notes due 2028 at 1.75%, repurchased $434M of 2024 notes.
- Eplontersen Phase 3 shows improvement through 85 weeks; PDUFA date Dec 22, 2023.
- Donidalorsen OASIS-HAE and eplontersen CARDIO-TTRansform enrollment complete; data H1:2024 and H1:2025.
- SPINRAZA royalties flat at $61M in Q2; Biogen's QALSODY approved for SOD1-ALS.

## SEC filing metadata
- accession: 0001140361-23-038715
- form_type: 8-K
- ticker: IONS
- cik: 0000874015
- company_name: IONIS PHARMACEUTICALS INC
- filed_at: 2023-08-09T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/874015/000114036123038715/0001140361-23-038715-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/874015/000114036123038715/brhc20057227_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-23-038715
- JSON: https://secwatch.observer/filing/0001140361-23-038715.json
- Plain text: https://secwatch.observer/filing/0001140361-23-038715.txt

## Key facts
- Earnings Releases
  IONIS PHARMACEUTICALS INC reported financial results for second quarter 2023; six months ended June 30, 2023.
  - Period: second quarter 2023; six months ended June 30, 2023
  - Result: reported results
  source text: Ionis reports second quarter 2023 financial results
  evidence_url: https://www.sec.gov/Archives/edgar/data/874015/000114036123038715/0001140361-23-038715-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.